Institut National de Recherche Biomedicale (INRB)
46
8
11
26
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.5%
3 terminated/withdrawn out of 46 trials
89.7%
+3.1% vs industry average
22%
10 trials in Phase 3/4
19%
5 of 26 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (46)
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
Role: collaborator
RVF and Other Emerging Infectious Diseases in East and Central Africa
Role: collaborator
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Role: collaborator
Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
Role: collaborator
Stop Transmission of Gambiense Human African Trypanosomiasis
Role: collaborator
Implementation and Evaluation of Vector Control Methods in Kinshasa: The Case of Aedes
Role: collaborator
Surveillance of AMR in DRC
Role: collaborator
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC
Role: collaborator
Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo
Role: collaborator
Azithromycin Reduction to Reach Elimination of Trachoma B
Role: collaborator
Ocular Complications of Mpox in the Democratic Republic Congo
Role: collaborator
Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC
Role: collaborator
EBOla Post-Exposure Prophylaxis
Role: collaborator
International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
Role: collaborator
Tecovirimat for Treatment of Monkeypox Virus
Role: collaborator
Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)
Role: collaborator
Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only
Role: collaborator
Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1)
Role: collaborator
Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)
Role: collaborator
Monkeypox, Biology, Outcome, Transmission and Epidemiology -Prospective Follow-up of High-risk Contacts
Role: collaborator